Letrozole, marketed under the brand name Femara, is an oral medication categorized as a non-steroidal aromatase inhibitor. It is predominantly used in the treatment of hormone-receptor-positive breast cancer in postmenopausal women. By inhibiting the enzyme aromatase, letrozole significantly reduces the production of estrogen in the body. While its primary role is in oncology, it has also been used off-label in certain fertility treatments and conditions where estrogen reduction is beneficial. Its high efficacy in reducing estrogen levels makes it a valuable tool in managing estrogen-dependent cancers and conditions where excessive estrogen may be detrimental.
Deep dive
Tap a section to expand.
Known interactions
Category rule: supplement × medication
Note
Some supplements change how the body processes medications (absorption, liver enzymes, or additive effects).
Specific pairs are checked against a licensed drug database and shown with their own severity. Always confirm with your provider or pharmacist.
Category rule: vitamin × medication
Note
Certain vitamins interact with specific medications (e.g., vitamin K with blood thinners).
Specific pairs are checked against a licensed source; confirm with your provider.
Frequently asked
Sources referenced
- NIH National Cancer Institute (various resources)
- FDA label for Letrozole (Femara)
- MedlinePlus (National Library of Medicine)
- PubChem (National Library of Medicine)
- The Cochrane Library
- DrugBank (University of Alberta)
Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Related compounds
Others in the medication category or studied for the same goals.
